Week in Review: China's Life Science Deals Top $1.4 Billion for Week

Deals and Financings - Harbin Gloria Pharma and WuXi Biologics out-licensed ex-China rights for a PD-1 antibody to California's Arcus Biosciences in an $818 million deal; - Shanghai's Zai Lab officially announced an IPO on the NASDAQ exchange that could raise as much as $115 million; - Lilly Asia Ventures closed its fourth China/Asia life science-focused fund at $450 million, a hard cap, according to China Money Network; - Shanghai Ankon Technologies raised $100 million to market NaviCam, a swallow-able device for imaging the gastric track to diagnose gastric disorders; - Shenzhen Royal Asset Management paid $33 million for China rights to three candidates aimed at fibrosis from Montreal's Prometic Life Sciences; - Antengene, a one-year-old Shanghai startup, completed a $21 million series A round for in-licensings, led by Qiming Venture Partners; - Ascletis of Hangzhou acquired China rights to a third HCV treatment from Medivir AB of Sweden, an addition to Ascletis' two other HCV treatments. Stock Symbols: (SHZ: 002437) (HK: 2269) (NYSE: LLY) (TSX: PLI; OTCQX: PFSCF) (NSDQ: MVIR) Share this with colleagues: // //